
Editor’s Note: At the 2026 European Society for Medical Oncology (ESMO) Congress, Professor Andrew Redfern, a medical oncologist at the University of Western Australia, presented the overall survival (OS) results of the Phase III MA.40/FINER study (FINER study; Abstract No. LBA14) in an oral presentation. The study showed that although ipatasertib plus fulvestrant significantly improved median progression-free survival (mPFS) in both the intention-to-treat (ITT) population and the AKT pathway-altered subgroup, this benefit did not translate into an OS improvement. Following the presentation, Oncology Frontier invited Professor Andrew Redfern to discuss the OS findings from the FINER study and the value of AKT pathway alterations as predictive biomarkers of treatment efficacy.
Study Overview
Background
The FINER study compared the efficacy and safety of the pan-AKT inhibitor ipatasertib plus fulvestrant versus placebo plus fulvestrant in patients with ER-positive/HER2-negative (ER+/HER2−) metastatic breast cancer (MBC) whose disease had progressed immediately after treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) combined with an aromatase inhibitor (AI).
The primary endpoint was investigator-assessed median PFS (mPFS) in the ITT population across the two treatment arms. The key secondary endpoint was mPFS in the AKT pathway-altered cohort. At a median follow-up of 15.2 months, the Phase III FINER study met its primary endpoint and first key secondary endpoint, demonstrating that the addition of ipatasertib to fulvestrant improved mPFS in both the ITT population and the AKT pathway-altered cohort. The OS analysis was presented at this year’s ESMO Congress.
Methods
Premenopausal, perimenopausal, and postmenopausal women, as well as men, with ER+/HER2− MBC were randomized 1:1 to receive either ipatasertib (400 mg orally once daily on Days 1–21) plus fulvestrant (500 mg intramuscularly on Days 1 and 15 of Cycle 1 and on Day 1 of subsequent cycles), or placebo plus fulvestrant.
Randomization was stratified according to AKT pathway alteration status (PIK3CA/AKT1/PTEN genomic alterations identified by circulating cell-free DNA [cfDNA] next-generation sequencing [NGS] versus wild-type/unknown status) and primary endocrine resistance (defined as ≤6 months of CDK4/6i treatment). OS was a secondary endpoint.
Results
A total of 250 participants were randomized to the ipatasertib arm (n=125) or the placebo arm (n=125). At a median follow-up of 35.0 months, 3.2% of participants in the ipatasertib arm and 2.4% in the placebo arm were still receiving protocol treatment.
In the ITT population, median OS was 26.68 months (95% CI, 21.42–30.78 months) in the ipatasertib arm versus 25.76 months (95% CI, 19.98–28.88 months) in the placebo arm (HR, 0.97; 95% CI, 0.70–1.33; P=0.83).
In an exploratory analysis, median OS in the AKT pathway-altered cohort was 23.66 months (95% CI, 18.53–28.65 months) versus 25.23 months (95% CI, 16.99–28.88 months), respectively (HR, 0.88; 95% CI, 0.56–1.39).
The mPFS improvement observed previously was maintained, with significant benefits continuing to be seen in both the ITT population and the AKT pathway-altered cohort. Updated mPFS in the ITT population was 5.36 versus 1.94 months (HR, 0.68; 95% CI, 0.52–0.88; P=0.0036). In the AKT pathway-altered cohort, updated mPFS was 5.45 versus 1.92 months (HR, 0.55; 95% CI, 0.37–0.81; P=0.0023).
The ipatasertib plus fulvestrant regimen was generally well tolerated, with a low rate of treatment discontinuation due to toxicity.
Conclusions
Despite a clinically meaningful improvement in PFS, fulvestrant plus ipatasertib did not improve OS in either the overall population or the AKT pathway-altered cohort when used as second-line treatment for ER+/HER2− MBC following CDK4/6i plus AI therapy.
Expert Interview
01
Oncology Frontier: At this year’s ESMO Congress, you presented the OS results of the FINER study. The study had previously reported its PFS data, showing that ipatasertib plus fulvestrant significantly prolonged PFS compared with the control arm in patients with CDK4/6 inhibitor-pretreated ER+/HER2− advanced breast cancer (5.32 months vs. 1.94 months; HR, 0.61). Could you tell us about the OS findings presented this time?
Professor Andrew D. Redfern: I am a medical oncologist and translational researcher based in Perth, Australia, and I served as a co-principal investigator (PI) of the FINER study alongside my collaborators in Canada.
In the OS analysis of this study, we did not observe an OS benefit in patients with or without AKT pathway alterations. There was also no OS benefit in the ITT population. However, we did observe a significant PFS benefit in the AKT pathway-altered cohort, with an HR of 0.55. In the AKT wild-type cohort, the HR was 0.75, which was not statistically significant (although I did not present these data at this year’s ESMO Congress).
These findings suggest that, at least in terms of PFS, AKT pathway alterations may serve as a reasonable biomarker for selecting patients who are likely to benefit from ipatasertib.
Professor Andrew D. Redfern
